A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 36, 2012, Pages 14526-14531

  Ng, Patrick P ^a   Jia, Ming ^a   Patel, Kedar G ^b   Brody, Joshua D ^a,c   Swartz, James R ^b   Levy, Shoshana ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stanford University   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Bispecific antibody fragments; Immunotherapy; Tumor speci fic antigen

Indexed keywords

ALPHA CD19 IDIOTYPE; CANCER VACCINE; CD19 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY ENGINEERING; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; IN VIVO STUDY; LYMPHOMA; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIGENS, CD19; B-LYMPHOCYTES; CANCER VACCINES; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FLOW CYTOMETRY; IMMUNOTHERAPY; LYMPHOMA; MICE; PLASMIDS; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 84865975048     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1211018109     Document Type: Article

References (42)

1. Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R (1998) Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 92:1184-1190. (Pubitemid 28369031)
2. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R (2004) Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 22:4717-4724.
3. Ai WZ, Tibshirani R, Taidi B, Czerwinski D, Levy R (2009) Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood 113:5743-5746.
4. Navarrete MA, et al. (2011) Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma. Blood 117:1483-1491.
5. Levy R, Robertson M, Leonard J, Vose J, Danney D (2008) Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non Hodgkin's lymphoma (FNHL). Ann Oncol 19(suppl 4):101-102.
6. Freedman A, et al. (2009) Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 27: 3036-3043.
7. Schuster SJ, et al. (2011) Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 29: 2787-2794.
8. Betting DJ, Kafi K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM (2008) Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas. J Immunol 181:4131-4140.
9. Carrasco YR, Batista FD (2007) B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity 27:160- 171.
10. Phan TG, Grigorova I, Okada T, Cyster JG (2007) Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat Immunol 8:992-1000. (Pubitemid 47300014)
11. Phan TG, Green JA, Gray EE, Xu Y, Cyster JG (2009) Immune complex relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation. Nat Immunol 10:786-793.
12. Ferguson AR, Youd ME, Corley RB (2004) Marginal zone B cells transport and deposit IgM-containing immune complexes onto follicular dendritic cells. Int Immunol 16: 1411-1422. (Pubitemid 39341554)
13. Gretz JE, Norbury CC, Anderson AO, Proudfoot AE, Shaw S (2000) Lymph-borne chemokines and other low molecular weight molecules reach high endothelial venules via specialized conduits while a functional barrier limits access to the lymphocyte microenvironments in lymph node cortex. J Exp Med 192:1425-1440.
14. Roozendaal R, et al. (2009) Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. Immunity 30:264-276.
15. Fearon DT, Carroll MC (2000) Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 18:393-422. (Pubitemid 30365386)
16. Goerke AR, Swartz JR (2008) Development of cell-free protein synthesis platforms for disulfide bonded proteins. Biotechnol Bioeng 99:351-367. (Pubitemid 351158284)
17. Kanter G, et al. (2007) Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. Blood 109:3393-3399. (Pubitemid 46572528)
18. Shoham T, et al. (2003) The tetraspanin CD81 regulates the expression of CD19 during B cell development in a postendoplasmic reticulum compartment. J Immunol 171: 4062-4072. (Pubitemid 37238681)
19. Tao MH, Levy R (1993) Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755-758.
20. Syrengelas AD, Chen TT, Levy R (1996) DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 2:1038-1041. (Pubitemid 26306846)
21. King CA, et al. (1998) DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 4: 1281-1286. (Pubitemid 28512109)
22. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW (1999) Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 17:253-258. (Pubitemid 29122633)
23. Fredriksen AB, Bogen B (2007) Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood 110:1797-1805. (Pubitemid 47443890)
24. Biragyn A, et al. (2004) Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood 104:1961-1969. (Pubitemid 39297844)
25. Schiavo R, et al. (2006) Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood 107: 4597-4605. (Pubitemid 43882603)
26. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT (1996) C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity. Science 271:348-350.
27. Lou D, Kohler H (1998) Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide. Nat Biotechnol 16:458-462. (Pubitemid 28211199)
28. Suradhat S, et al. (2001) Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization. Vet Immunol Immunopathol 83:79-92. (Pubitemid 32927187)
29. Gor DO, Ding X, Li Q, Greenspan NS (2006) Genetic fusion of three tandem copies of murine C3d sequences to diphtheria toxin fragment B elicits a decreased fragment B-specific antibody response. Immunol Lett 102:38-49. (Pubitemid 41606038)
30. Pulczynski S, Boesen AM, Jensen OM (1993) Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: An immunofluorescence and immunoelectron microscopy study. Blood 81:1549-1557. (Pubitemid 23083834)
31. Du X, Beers R, Fitzgerald DJ, Pastan I (2008) Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res 68:6300-6305.
32. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN (1972) Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci USA 69:1540-1544.
33. George AJ, Tutt AL, Stevenson FK (1987) Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J Immunol 138:628-634. (Pubitemid 17002231)
34. Kaminski MS, Kitamura K, Maloney DG, Levy R (1987) Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol 138:1289-1296. (Pubitemid 17017921)
35. Carroll WL, Starnes CO, Levy R, Levy S (1988) Alternative V kappa gene rearrangements in a murine B cell lymphoma. An explantation for idiotypic heterogeneity. J Exp Med 168:1607-1620. (Pubitemid 19023250)
36. Thornton BP, Větvicka V, Ross GD (1994) Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. J Immunol 152:1727-1737.
37. Sixt M, et al. (2005) The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 22:19-29. (Pubitemid 40143448)
38. De Groot AS, et al. (2008) Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 112:3303-3311.
39. Ding C, Wang L, Marroquin J, Yan J (2008) Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1. Blood 112:2817-2825.
40. DiLillo DJ, et al. (2008) Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 180:361-371.
41. Takata T, et al. (2009) Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematop 49:9-13.
42. Patel KG, et al. (2009) Cell-free production of Gaussia princeps luciferase - antibody fragment bioconjugates for ex vivo detection of tumor cells. Biochem Biophys Res Commun 390:971-976.